The Keck School of Medicine of USC and the USC Viterbi School of Engineering have announced that the Alfred E. Mann Department of Biomedical Engineering will become a joint department between the two schools, forging a formal partnership in education, research and innovation in technology and medicine. This joint department, one of the first of its kind in California, builds on decades of cross-disciplinary research and breakthroughs at USC, including the world’s first FDA-approved artificial retina, the first brain implant to restore lost memory function, and innovations in immunotherapy to treat cancer. With added support from USC’s president and provost, the newly integrated biomedical engineering department will create new structures and gain new resources dedicated to further accelerating biomedical innovation, enriching educational programs and advancing technology in medicine. It will combine expertise in priority areas spanning medical devices, neuroengineering, imaging science, drug discovery, artificial intelligence (AI) and informatics, cellular and molecular bioengineering, and more. Facilities at both the Viterbi School of Engineering and the Keck School of Medicine will be devoted to the joint department, with the chair reporting to both deans. Yingxiao (Peter) Wang, PhD, the department’s current chair, who also holds the Dwight C. and Hildagarde E. Baum Chair in Biomedical Engineering, will help implement the transition by leading the department into its next phase.

BUFFALO, NY – March 31, 2026 – A new research paper was published in Volume 17 of Oncotarget on March 27, 2026, titled “The SCD1 inhibitor aramchol interacts with regorafenib and metformin to kill tumor cells.”

Hiroshima University researchers have developed a practical framework to identify candidate pathogenic variants hidden among the large number of variants of uncertain significance (VUS) detected in comprehensive genomic profiling (CGP) of cancers. This framework could improve the accuracy of precision oncology by more reliable prioritization of VUS.  

Researchers at the Josep Carreras Leukaemia Research Institute have demonstrated that combining data from different origins enables a more precise characterisation of cell type’s diversity into tissues and organs. The team also introduced scOMM, a new machine learning tool for classifying and compare cell types across the distinct data modalities. The tool is openly available to researchers worldwide and has been successfully tested in kidney tissue, one of the most cellularly diverse organs in the human body and validated in blood and heart tissue. As the results demonstrate, when it comes to understanding complex tissues, the whole is greater than the sum of its parts.

Microbial metabolites influence health far beyond the intestinal tract. Yet, a systematic understanding of how these molecules precisely control specific immune cell functions and regulate disease has remained elusive. A comprehensive review by the team of Professor Changtao Jiang and Dr. Kai Wang at Peking University addresses this gap. The article provides a critical theoretical foundation for understanding the gut microbiota-metabolite-immune axis in disease pathogenesis and for developing targeted intervention strategies.